bioAffinity
  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Select Page

bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer

by Maria Zannes | May 1, 2023 | Press Releases

SAN ANTONIO, Texas (May 1, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced that Michael Dougherty has joined the company...

bioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium

by Maria Zannes | Apr 25, 2023 | Press Releases

SAN ANTONIO, Texas (April 25, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, will present at the Cleveland Clinic’s invitation-only...

bioAffinity CEO Will Be Featured Speaker at AGC Luncheon April 25

by Maria Zannes | Apr 18, 2023 | Events

APRIL 18, 2023 bioAffinity Technologies President and CEO Maria Zannes will address the Austin/San Antonio chapter of the Association for Corporate Growth (ACG) at a luncheon event on Tuesday, April 25, 2023. ACG is a global community for middle-market dealmakers and...

bioAffinity Technologies to Ring Nasdaq Closing Bell Today

by Maria Zannes | Apr 5, 2023 | Press Releases

SAN ANTONIO, Texas (April 5, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, will ring the Nasdaq Stock Market closing bell this...

bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results

by Maria Zannes | Mar 31, 2023 | Press Releases

Conference Call Scheduled for April 3, 2023, at 9:00 a.m. Eastern Time SAN ANTONIO, Texas (March 31, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and...
« Older Entries
Next Entries »

Categories

  • Articles (28)
  • Events (38)
  • News (53)
  • Press Releases (139)
  • Publications (17)

Recent Posts

  • bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025 September 17, 2025
  • Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules September 9, 2025
  • U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA September 3, 2025
  • New Test Shows Promise for Improving Lung Cancer Detection, Reducing Costs for VA – US Medicine, the Voice of Federal Medicine August 29, 2025
  • bioAffinity Technologies Appoints New Members to Board of Directors August 18, 2025
CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Copyright © 2023 bioAffinity Technologies, Inc.